CD4 and non-small cell lung carcinoma: Zappasodi et al. found that a subset of CD4+Foxp3– T cells with high PD-1 expression (4PD1hi) can inhibit T cell function and the decreased 4PD1hi frequencies may correlate with favorable clinical outcome after PD-1 blockade in NSCLC (117).